ALTSTATION.IO

Healthpeak Properties, Inc. (DOC) Stock Analysis

By Nova Skye | AltStation.io | Updated October 13, 2026

Price

$18.80

Change

+0.03%

Market Cap

$13.33B

Avg Volume

5.5M

Company Overview

Healthpeak Properties is an S&P 500 healthcare real estate investment trust headquartered in Denver, Colorado. The company makes money by owning, developing, and leasing specialized facilities tailored for healthcare discovery and delivery. Its core revenue comes from two asset types: laboratory real estate leased to life science companies and outpatient medical buildings leased to health systems and physician groups. The business has operated continuously in the healthcare real estate sector since incorporating in Maryland in 1985.

Healthpeak is an established heavyweight in healthcare facilities, managing a portfolio of approximately 52 million square feet. Roughly 40 million square feet of that footprint is concentrated in outpatient medical properties across growth markets like Dallas, Houston, and Phoenix. Their competitive advantage comes from deep integration with major health systems, which keeps occupancy steady and tenant retention high. They face direct competition from healthcare peers like Ventas and Healthcare Realty Trust, while their lab properties remain sensitive to broader biotech funding cycles.

Healthpeak pulled off a major consolidation by completing an all-stock merger with Physicians Realty Trust on March 1, 2024, creating a combined entity valued at roughly 21 billion dollars and switching its ticker to DOC. This deal decisively scaled their outpatient medical network and created a more defensive cash-flow profile. Management is now focused on extracting operational synergies from the combined platform and keeping balance sheet leverage in check.

Key Financials

Market Cap

$13.33B

Revenue

$2.95B

EBITDA

$1.57B

Gross Margin

57.6%

Profit Margin

8.2%

Revenue Growth

11.1%

Total Cash

$1.64B

Total Debt

$10.32B

Free Cash Flow

$1.65B

52-Week Price Performance Analysis

Price Statistics

P/E Ratio

53.73

Forward P/E

134.32

Beta

0.99

52-Week High

$22.95

52-Week Low

$15.70

EPS

$0.35

50-Day Avg

$20.55

200-Day Avg

$18.95

Price/Book

1.65

Technical Analysis

DOC trades at $18.80, roughly halfway through its technical 52-week range of $14.96 to $22.72. The stock sits 51% of the way from the low to the high, down 16.60% from the peak but up 26.64% from the bottom. Price is 4.20% below the 20-day moving average of $19.78, showing that the short-term trend remains weak. Five-day momentum is positive at 0.58%, but 20-day momentum is still negative at 6.97%. Near-term support is $18.52, while $20.92 is the resistance level buyers need to break.

Recent News and Developments

DOC slides, then recovers to $18.95

DOC fell 1.79% on October 7 and another 0.75% on October 8, closing at $18.52. It rebounded 1.51% on October 9 and 0.80% on October 12 to finish at $18.95. Source: Stock Analysis

Raymond James maintains Hold rating

Raymond James analyst Dave Rodgers maintained a Hold rating on Healthpeak Properties on October 6. The broader analyst consensus was also Hold, with an average price target of $22.41 and 18.8% implied upside from the cited reference price. Source: AD HOC NEWS

Bullish analyst calls DOC a Strong Buy

A Seeking Alpha analyst maintained a Strong Buy rating on October 12, citing a 6.5% dividend yield and a forward price-to-FFO multiple of 10.65. The stock’s historical price-to-FFO multiple was listed at 14.0, supporting the analyst’s valuation argument. Source: Seeking Alpha

Market Sentiment and Analyst Recommendations

Bull Case

Revenue grew 11.1% to $2.95 billion, giving DOC a real fundamental growth argument. The analyst target is $22.95, compared with the current $18.80 price, and the high-end target reaches $29.00. The broader recommendation is buy based on 19 analysts. A bullish October 12 analysis cited a 6.5% dividend yield and a forward price-to-FFO multiple of 10.65, below the listed historical multiple of 14.0. The $1.22 annualized dividend consumes about 69.7% of midpoint 2026 adjusted FFO guidance, indicating that current coverage holds. DOC offers income, revenue growth, and analyst-backed upside at a price still 16.60% below its technical 52-week high.

Bear Case

The trailing P/E of 53.73 is expensive and leaves little room for operational disappointment. Total debt is $10.32 billion against $1.64 billion in cash, creating a substantial balance-sheet burden. The lab portfolio is the clearest operational problem: occupancy was 78.5%, while same-store adjusted net operating income fell 3.2% year over year. Price is below the $19.78 moving average, and 20-day momentum is negative at 6.97%. Raymond James maintained a Hold rating on October 6, while the broader consensus cited in that report was also Hold. The analyst target range extends down to $17.00, so the bullish consensus does not eliminate downside risk.

What to Watch

The first test is whether DOC holds the $18.52 near-term support level after closing there on October 8. A move back above the $19.78 moving average would show that the recent recovery is gaining traction. The larger technical hurdle is $20.92, the 30-day high and near-term resistance. Investors should track whether lab occupancy improves from 78.5% and whether same-store adjusted net operating income recovers from its 3.2% year-over-year decline. Dividend coverage also matters: the $1.22 annualized payout currently consumes about 69.7% of midpoint 2026 adjusted FFO guidance. The thesis strengthens if revenue growth holds near 11.1% and the lab portfolio improves; it weakens if DOC loses $18.52 or dividend coverage deteriorates.

Analyst Consensus

BUY

Based on 19 analyst opinions

Low Target

$17.00

Mean Target

$22.95

High Target

$29.00

Earnings and Financial Data

Sector

Real Estate

Industry

REIT – Healthcare Facilities

Employees

411

Earnings & Dividends

Next Earnings

Nov 02, 2026

EPS (Trailing)

$0.35

Dividend Yield

649.0%

Payout Ratio

348.6%

Frequently Asked Questions

Is DOC a good stock to buy?

DOC carries a buy recommendation from 19 analysts and has 11.1% revenue growth. The takeaway is that analysts are positive, but the 53.73 P/E demands solid execution.

What is DOC’s price target?

The analyst target is $22.95, with estimates ranging from $17.00 to $29.00. The takeaway is that expectations vary widely despite the consensus upside case.

What is Healthpeak Properties worth?

Healthpeak Properties has a market capitalization of $13.33 billion and revenue of $2.95 billion. The takeaway is that DOC is a large company trading at a 53.73 P/E.

What is DOC’s 52-week trading range?

The supplied key-data range is $15.70 to $22.95, while the technical price series shows an exact range of $14.96 to $22.72. At $18.80, the takeaway is that DOC sits 51% of the way from the technical low to the high.

What are DOC’s support and resistance levels?

Near-term support is $18.52, and near-term resistance is $20.92. The takeaway is that those are the main levels to watch while DOC trades below its $19.78 moving average.

Related Stock Reports

Disclaimer: This report is for informational purposes only and does not constitute financial advice. The analysis and opinions expressed are those of AltStation.io and should not be relied upon as the sole basis for investment decisions. Always conduct your own research and consult with a qualified financial advisor before making investment decisions. Past performance does not guarantee future results. Updated October 13, 2026.